See step-by-step instructions on how to take Pulmozyme (dornase alfa)
Before taking or administering Pulmozyme, it is important that you receive training from your CF Care Team.
They are experiencing a lot of different emotions and may need someone to talk to. Let them know you’re there to help them work through any feelings they may be having.
Older children may begin to feel pressured to fit in with their friends at school. You can help them by making your home as comfortable as possible. Encourage the rest of your family, including siblings, to be supportive as well.
As teenagers are more independent than preteens, they may resist your efforts to manage every aspect of their care. By stressing the importance of honesty and transparency, you can allow them to handle more and more of their treatment while avoiding “helicopter parenting”.
More consistent treatment means more quality time with friends and more time for the activities your child loves. These positive outcomes can motivate your child to create a treatment routine.
You and your child are dealing with a busy schedule, so it’s important that you both have time for fun activities. Set aside some time each week to go to the park or cook a special dinner together.
Give your son or daughter a letter outlining their CF treatment that they can share with their teachers and school nurse. This may help your child explain the basic facts of their condition and treatment process. You can write the letter yourself, with advice from a doctor.
Your child likely qualifies for an Individual Education Plan (IEP) under the Individuals with Disabilities Education Act (IDEA).
Your CF doctor can work with the school administration to establish your child’s needs, and lay the foundation for accommodations, such as excused absences and tutors for when your child is too sick to attend school.
Stress the importance of daily routines, even if they require waking up early for treatment.
The safety and effectiveness of Pulmozyme have been established in patients 5 years of age and older. The safety of Pulmozyme, 2.5 mg by inhalation, was studied with 2 weeks of daily administration in 65 patients with cystic fibrosis aged 3 months to <5 years. While clinical trial data are limited in pediatric patients younger than 5 years of age, the use of Pulmozyme should be considered for pediatric cystic fibrosis patients who may experience potential benefit in pulmonary function, or who may be at risk of respiratory tract infection.
Pulmozyme (dornase alfa) is indicated, along with standard therapies, for the management of pediatric and adult patients with cystic fibrosis (CF) to improve pulmonary function.
In CF patients with an FVC ≥ 40% of predicted, daily administration of Pulmozyme has also been shown to reduce the risk of respiratory tract infections requiring injectable antibiotics.
Pulmozyme should not be used in patients who are allergic to any of its ingredients.
Patients may experience the following when using Pulmozyme: change in or loss of their voice, discomfort in the throat, rash, chest pain, red watery eyes, runny nose, lowering of lung function, fever, indigestion, and shortness of breath. There have been no reports of severe allergic reactions caused by the administration of Pulmozyme. Mild to moderate hives and mild skin rash have been observed and have been short-lived.
The safety and effectiveness of Pulmozyme along with standard therapies for cystic fibrosis have been established in pediatric patients. The use of Pulmozyme in pediatric patients at 5 to 17 years of age is supported by evidence from a randomized, controlled trial. The use of Pulmozyme in patients less than 5 years of age is supported by the efficacy data from the same randomized, controlled trial and additional safety data in pediatric patients aged 3 months to less than 5 years who received Pulmozyme.
You are encouraged to report side effects to Genentech and the FDA. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.
For further information, please see the Pulmozyme full Prescribing Information. If you have questions, please discuss them with your CF Care Team.
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.